Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis

Uri Landes, Zaza Iakobishvili, Daniella Vronsky, Oren Zusman, Alon Barsheshet, Ronen Jaffe, Ayman Jubran, Sung Han Yoon, Raj R. Makkar, Maurizio Taramasso, Marco Russo, Francesco Maisano, Jan Malte Sinning, Jasmin Shamekhi, Luigi Biasco, Giovanni Pedrazzini, Marco Moccetti, Azeem Latib, Matteo Pagnesi, Antonio ColomboCorrado Tamburino, Paolo D' Arrigo, Stephan Windecker, Thomas Pilgrim, Didier Tchetche, Chiara De Biase, Mayra Guerrero, Omer Iftikhar, Johan Bosmans, Edo Bedzra, Danny Dvir, Darren Mylotte, Horst Sievert, Yusuke Watanabe, Lars Søndergaard, Hanna Dagnegård, Pablo Codner, Susheel Kodali, Martin Leon, Ran Kornowski

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Objectives: The authors sought to collect data on contemporary practice and outcome of transcatheter aortic valve replacement (TAVR) in oncology patients with severe aortic stenosis (AS). Background: Oncology patients with severe AS are often denied valve replacement. TAVR may be an emerging treatment option. Methods: A worldwide registry was designed to collect data on patients who undergo TAVR while having active malignancy. Data from 222 cancer patients from 18 TAVR centers were compared versus 2,522 “no-cancer” patients from 5 participating centers. Propensity-score matching was performed to further adjust for bias. Results: Cancer patients’ age was 78.8 ± 7.5 years, STS score 4.9 ± 3.4%, 62% men. Most frequent cancers were gastrointestinal (22%), prostate (16%), breast (15%), hematologic (15%), and lung (11%). At the time of TAVR, 40% had stage 4 cancer. Periprocedural complications were comparable between the groups. Although 30-day mortality was similar, 1-year mortality was higher in cancer patients (15% vs. 9%; p < 0.001); one-half of the deaths were due to neoplasm. Among patients who survived 1 year after the TAVR, one-third were in remission/cured from cancer. Progressive malignancy (stage III to IV) was a strong mortality predictor (hazard ratio: 2.37; 95% confidence interval: 1.74 to 3.23; p < 0.001), whereas stage I to II cancer was not associated with higher mortality compared with no-cancer patients. Conclusions: TAVR in cancer patients is associated with similar short-term but worse long-term prognosis compared with patients without cancer. Among this cohort, mortality is largely driven by cancer, and progressive malignancy is a strong mortality predictor. Importantly, 85% of the patients were alive at 1 year, one-third were in remission/cured from cancer.

Original languageEnglish (US)
Pages (from-to)78-86
Number of pages9
JournalJACC: Cardiovascular Interventions
Issue number1
StatePublished - Jan 14 2019


  • AS
  • TAVR
  • aortic stenosis
  • cancer
  • malignancy
  • transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis'. Together they form a unique fingerprint.

Cite this